Dr. Mark Chesnutt, MD

Critical Care Medicine Portland, OR Male
NPI: 1891892667
Total Payments
$15,088
2024 Payments
$9,440
Companies
2
Transactions
9
Medicare Patients
11
Medicare Billing
$1,562

Payment Breakdown by Category

Research$15,040 (99.7%)
Food & Beverage$47.72 (0.3%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $15,040 7 99.7%
Food and Beverage $47.72 2 0.3%

Payments by Type

Research
$15,040
7 transactions
General
$47.72
2 transactions

Top Paying Companies

Company Total Records Latest Year
Regeneron Pharmaceuticals, Inc. $15,040 7 $0 (2024)
Stryker Corporation $47.72 2 $0 (2023)

Payment History by Year

Year Amount Transactions Top Company
2024 $9,440 4 Regeneron Pharmaceuticals, Inc. ($9,440)
2023 $1,648 3 Regeneron Pharmaceuticals, Inc. ($1,600)
2022 $4,000 2 Regeneron Pharmaceuticals, Inc. ($4,000)

All Payment Transactions

9 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
09/24/2024 Regeneron Pharmaceuticals, Inc. — — Cash or cash equivalent $2,720.00 Research
Study: PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND EFFICACY OF GARETOSMAB IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
05/14/2024 Regeneron Pharmaceuticals, Inc. — — Cash or cash equivalent $2,400.00 Research
Study: PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND EFFICACY OF GARETOSMAB IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
03/19/2024 Regeneron Pharmaceuticals, Inc. — — Cash or cash equivalent $2,240.00 Research
Study: PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND EFFICACY OF GARETOSMAB IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
01/04/2024 Regeneron Pharmaceuticals, Inc. — — Cash or cash equivalent $2,080.00 Research
Study: PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND EFFICACY OF GARETOSMAB IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
09/28/2023 Regeneron Pharmaceuticals, Inc. — — Cash or cash equivalent $1,600.00 Research
Study: PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND EFFICACY OF GARETOSMAB IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
06/15/2023 Stryker Corporation SPINEJACK (Device) Food and Beverage In-kind items and services $32.65 General
Category: INTERVENTIONAL SPINE
06/15/2023 Stryker Corporation SPINEJACK (Device) Food and Beverage In-kind items and services $15.07 General
Category: INTERVENTIONAL SPINE
12/20/2022 Regeneron Pharmaceuticals, Inc. — — Cash or cash equivalent $960.00 Research
Study: Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva
10/25/2022 Regeneron Pharmaceuticals, Inc. — — Cash or cash equivalent $3,040.00 Research
Study: Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva

Research Studies & Clinical Trials

Study Name Company Amount Records
PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND EFFICACY OF GARETOSMAB IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA Regeneron Pharmaceuticals, Inc. $11,040 5
Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva Regeneron Pharmaceuticals, Inc. $4,000 2

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2022 1 11 11 $5,379 $1,562
Total Patients
11
Total Services
11
Medicare Billing
$1,562
Procedure Codes
1

All Medicare Procedures & Services

1 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2022 11 11 $5,379 $1,562 29.0%

About Dr. Mark Chesnutt, MD

Dr. Mark Chesnutt, MD is a Critical Care Medicine healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891892667.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Chesnutt, MD has received a total of $15,088 in payments from pharmaceutical and medical device companies, with $9,440 received in 2024. These payments were reported across 9 transactions from 2 companies. The most common payment nature is "" ($15,040).

As a Medicare-enrolled provider, Chesnutt has provided services to 11 Medicare beneficiaries, totaling 11 services with total Medicare billing of $1,562. Data is available for 1 year (2022–2022), covering 1 distinct procedure/service records.

Practice Information

  • Specialty Critical Care Medicine
  • Other Specialties Pulmonary Disease
  • Location Portland, OR
  • Active Since 09/20/2006
  • Last Updated 07/10/2007
  • Taxonomy Code 207RC0200X
  • Entity Type Individual
  • NPI Number 1891892667

Products in Payments

  • SPINEJACK (Device) $47.72

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Critical Care Medicine Doctors in Portland

David Hotchkin, Md, MD

Critical Care Medicine — Payments: $57,119

Critical Care Medicine $57,119

Gopal Allada, Md, MD

Critical Care Medicine — Payments: $37,391

Critical Care Medicine $37,391

Dr. Ralph Juarez, M.d, M.D

Critical Care Medicine — Payments: $32,116

Critical Care Medicine $32,116

Dr. Heidi Deblock, M.d, M.D

Critical Care Medicine — Payments: $28,066

Critical Care Medicine $28,066

David Jacoby, Md, MD

Critical Care Medicine — Payments: $27,948

Critical Care Medicine $27,948

Andrea Orfanakis, Md, MD

Critical Care Medicine — Payments: $9,181

Critical Care Medicine $9,181